Boston Scientific and Johnson & Johnson are gearing up for a courtroom showdown, as the companies prepare for a multibillion-dollar trial over a breach-of-contract suit related to a failed bidding war for devicemaker Guidant.
Johnson & Johnson's Ethicon unit scored a victory in its ongoing vaginal mesh litigation as a federal judge in Texas tossed out 76 liability lawsuits related to the company's pelvic mesh devices.
The only FDA-approved, wearable cancer treatment device may expand its reach. A Phase III trial of Optune (NovoTTF-100A System) from Novocure was halted early due to statistically significant efficacy for the device in combination with chemotherapy to treat newly diagnosed glioblastoma patients.
Days after finally getting the FDA's go-ahead to resume the stop-and-start development of its lead candidate, Geron has signed a deal to cut Johnson & Johnson in on the process, putting the biotech in line for as much as $935 million if all goes according to plan.
China's registration review process for imported medical devices and in vitro diagnostics has been shortened under new China FDA importation regulations that took effect last month, and companies that fail to follow the guidelines will not get a second chance, meaning any mistakes could prove fatal to a product's chances in China.
A couple of years ago, Dendreon sold off a manufacturing plant to Novartis for $40 million-plus to raise some quick cash. Now, someone can pick up its two remaining manufacturing facilities, a logistics center and headquarters in Seattle and its one-time promising drug, Provenge, for as little as $275 million.
Ironically, Johnson & Johnson is suing Boston Scientific for preventing it from acquiring ill-fated stent maker Guidant, thereby sparing the plaintiff from the $6 billion-plus in write-offs that Boston Scientific has incurred in the years following its 2006 acquisition.
Bribery and pricing investigations aren't scaring Johnson & Johnson away from China. CEO Alex Gorsky tells The Wall Street Journal that his company is expanding full speed ahead in the fast-growing emerging market--and is actively looking at deals there to boost pharma sales.
Johnson & Johnson CEO Alex Gorsky likes to hint at trouble developing its Chinese sales, but don't expect him to come right out and criticize the prickly Chinese government. In an brief interview with The Wall Street Journal, Gorsky said J&J was looking for new acquisitions in China, with new drugs for lung cancer as one of its topic targets.
Johnson & Johnson just scored a marketing goal: Its hepatitis C drug Olysio won FDA approval as part of a two-drug cocktail that also stars Gilead Sciences' Sovaldi. The question now is how much that approval will help Olysio withstand competition, both current and forthcoming.